Search Results

The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either treatment alone (31.0 percent and 20.8 percent, respectively) at 38 weeks1

Cold temps and dry air can wreak havoc on already stressed skin. For those with certain inflammatory skin diseases, Lloyd S. Miller, M.D., Ph.D., says following a personalized treatment plan is the key to finding more comfort this season.

Two experts in the field share the latest understanding and research into conditions like pediatric plaque psoriasis, juvenile idiopathic arthritis and pediatric active psoriatic arthritis—diseases that afflict children and can have long-term damaging effects into adulthood if not properly treated.

They’re such a staple of everyday life that it’s hard to imagine they weren’t always around. We trace the iconic product’s backstory—including a trip to the moon!

With COVID-19 dominating the news this year, chances are you’ve also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.

The iconic product has been around for 75 years. Learn about the “aha” moment that sparked the idea for its creation, the U.S. president who pushed it forward—and how Johnson & Johnson helped bring it to market.

Over its more than 130-year history, the company produced some unexpected products, like holiday-themed gift wrap tape. In-house historian Margaret Gurowitz delves into the details behind the company’s foray into decorative tape.

Born in 1845, Robert Wood Johnson I is best known for his pioneering innovations in sterile surgery and sanitary wound care. The company’s future-oriented focus, acceptance of women in professional roles and management for the long-term also have their origins with Johnson, whose founding ideals would later find expression in Our Credo, written by his son Robert Wood Johnson II.

STELARA when used as a first-line therapy was associated with longer time in clinical remission or clinical response, including the postponing of surgery, among adult patients with moderately to severely active ulcerative colitis compared with usage as a second- or third-line therapy in a modelled analysis Bio-naïve patients with moderately to severely active Crohn’s disease started on STELARA showed higher rates of persistence at one year compared to adalimumab in a retrospective real-world evidence study

For the first installment of our J&J Lightbulb Moment series—which looks at pivotal “aha moments” at the company that had a lasting impact on healthcare—we delve into how a chance meeting on a cross-country trip inspired a life-changing invention.